Single tranexamic acid dose to reduce perioperative morbidity in primary total hip replacement: a randomised clinical trial

摘要

IntroductionAlthough prophylactic tranexamic acid (TXA) is a safe, low-cost option to reduce bleeding in patients undergoing total hip replacement (THR), its optimal dose and duration is unknown. We compared the safety and effectiveness of TXA given as either a single injection or continuous infusion in THR patients, hypothesising that a second TXA dose would not offer any clinical advantages over the single injection.